Cite
HARVARD Citation
Murthy, R. et al. (2018). Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet oncology. 19 (7), pp. 880-888. [Online].